Grifols S A : January 26, 2022Grifols maintains its standing in the Bloomberg Gender-Equality Index for its commitment to equality

Grifols maintains its standing in the

Bloomberg Gender-Equality Index for its

commitment to equality

• For the second consecutive year, Grifols is part of the Bloomberg Gender- Equality Index (GEI), reaffirming its commitment to equality, female leadership and talent promotion.
• Currently, 60% of Grifols' human team is made up of women.
• The company's goal is to have 50% of its senior management made up of women by 2030.
• Grifols is also part of the Dow Jones Sustainability World Index (DJSI), Vigeo Euronext and FTSE4Good.

Barcelona, January 26, 2022.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines with a proven track record of more than 110 years contributing to people's health and well-being, has been included, for the second consecutive year in 2022, in the "Bloomberg Gender-Equality Index" (GEI).

Grifols reaffirms its commitment to the advancement of women in the labor market through policies that promote women's professional careers and a greater female representation in the organization. Currently, 60% of employees are women, who in 98% of cases have permanent contracts.

Being a part of this index reflects Grifols' constant involvement with equality, gender diversity and fundamental human rights, as well as its vocation, for more than a hundred years, to promote the talent and full potential of its employees in an equal, inclusive and non- discriminatory way.

Within the framework of this commitment, Grifols launched a Diversity and Inclusion Plan in 2021 aimed at continuing to bolster progress and being another catalyst for improvement in this area, positioning the company as a reference for diversity and inclusion. The company's goal for 2030 is to have 50% of its senior management made up of women.

For Montse Gaja, Chief of Human Resources at Grifols: "Continuing to be a part of this index is a source of pride. It reflects our commitment to continue being a reference in equality and diversity, as well as our efforts to foster an inclusive culture in which women feel empowered, qualified and are visible in the organization. True to our values, we will remain committed to advancing these fundamental principles, always placing our team as a priority".

Page 1 of 3

In addition, being a part of GEI reaffirms Grifols' efforts of continue contributing to the achievement of the Sustainable Development Goals (SDGs) promoted by the United Nations, specifically SDG 5 that refers to achieving gender equality and the empowerment of women, which the company promotes in its strategy and integrates into its Sustainability Master Plan.

A useful evaluation tool for investors

The Bloomberg Gender-Equality index provides transparency over the practices and policies related to gender equality and diversity in publicly-listed companies. This comprehensive information available in regards to the environmental, social and corporate governance (ESG) criteria, allows investors to benchmark companies' performance.

In its elaboration, a total of 70 metrics grouped in five pillars are analyzed: female leadership and talent promotion; equal pay and gender pay parity; inclusive culture; sexual harassment policies and pro-women campaigns.

Since December 2021, Grifols is part of the Dow Jones Sustainability World Index (DJSI). In 2020, the company became part of the DJSI Europe, Euronext Vigeo Europe 120 and the Euronext Vigeo Eurozone 120, and since 2018, it is also a member of the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex sustainability stock market indices.

For investors:

Investor Relations and Sustainability [e-mail] [e-mail] [e-mail]. [phone]

For media inquiries:

Duomo Communication - Grifols Press Office	Grifols Media Press Office
Tel. +34	91 311 92 89 - 91 311 92 90	[e-mail]
Raquel Lumbreras	Tel. [phone]
[e-mail]
Tel. +34	659 57 21 85
Borja Gómez
[e-mail]
Tel. +34	650 402 225

Page 2 of 3

About Grifols

Grifols is a global company in the health sector that has been working since 1909 to improve the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services in more than 100 countries.

A pioneer in the blood products industry, Grifols is one of the largest plasma companies, with a growing network of donation centers around the world. With the plasma obtained, Grifols produces essential medicines to treat chronic, rare and sometimes very serious diseases. As a recognized leader in transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from donation to transfusion. In addition, it provides hospitals, pharmacies and health professionals with the tools, information and services that contribute to offering specialized and efficient medical care.

Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that helps define the standards of continuous innovation, quality, safety and ethical leadership in the sector.

In 2020, Grifols' total economic impact in the main countries where it operates is estimated at 7,500 million euros and 140,000 jobs generated, including direct, indirect and induced jobs.

The company's ordinary shares (Class A) are listed on the Spanish Continuous Market and form part of the Ibex-35 (MCE: GRF). Grifols non-voting shares (Class B) are listed on the Spanish Continuous Market (MCE: GRF.P) and on the North American NASDAQ through ADR (American Depositary Receipts) (NASDAQ: GRFS).

For more information: www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group .

Page 3 of 3